Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 65% Improvement Relative Risk Mortality (b) -40% ICU admission 58% ICU time 68% Discharge, day 36 80% Discharge, day 28 85% Discharge, day 21 85% Discharge, day 14 65% Discharge, day 7 65% Recovery time, fever 45% Hospitalization time 50% c19early.org/d De Niet et al. NCT04636086 Vitamin D RCT LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Double-blind RCT 43 patients in Belgium (August 2020 - August 2021) Shorter hospitalization with vitamin D (p=0.003) De Niet et al., Nutrients, doi:10.3390/nu14153048 Favors vitamin D Favors control
Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
De Niet et al., Nutrients, doi:10.3390/nu14153048, NCT04636086 (history)
De Niet et al., Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized,.., Nutrients, doi:10.3390/nu14153048, NCT04636086
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT with 21 vitamin D and 22 placebo hospitalized patients in Belgium with vitamin D deficiency, showing significantly shorter hospitalization and improved clinical recovery with treatment.
risk of death, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, COVID-19 mortality.
risk of death, 39.7% higher, RR 1.40, p = 0.70, treatment 4 of 21 (19.0%), control 3 of 22 (13.6%), all cause including after discharge and non-COVID-19.
risk of ICU admission, 58.1% lower, RR 0.42, p = 0.41, treatment 2 of 21 (9.5%), control 5 of 22 (22.7%), NNT 7.6.
ICU time, 67.7% lower, relative time 0.32, p = 0.47, treatment 21, control 22.
risk of no hospital discharge, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 36.
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of no hospital discharge, 85.4% lower, RR 0.15, p = 0.23, treatment 0 of 21 (0.0%), control 3 of 22 (13.6%), NNT 7.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 21.
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 22 (13.6%), NNT 11, day 14.
risk of no hospital discharge, 65.1% lower, RR 0.35, p = 0.03, treatment 4 of 21 (19.0%), control 12 of 22 (54.5%), NNT 2.8, day 7.
recovery time, 45.4% lower, relative time 0.55, p = 0.06, treatment 21, control 22, fever.
hospitalization time, 50.0% lower, relative time 0.50, p = 0.003, treatment 21, control 22.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
De Niet et al., 26 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Belgium, peer-reviewed, 16 authors, study period August 2020 - August 2021, dosage 25,000IU days 1-4, 11, 18, 25, trial NCT04636086 (history).
Contact: sdeni@smb.be (corresponding author), mtrem@smb.be, mcoff@smb.be, afrouseau@chuliege.be, d.calmes@chuliege.be, affrix@chuliege.be, f.gester@chuliege.be, muriel.delvaux@chuliege.be, af.dive@chuliege.be, elora.guglielmi@chuliege.be, monique.henket@chuliege.be, alicia.staderoli@chuliege.be, renaud.louis@chuliege.be, j.guiot@chuliege.be, dmaesen@chuliege.be, etienne.cavalier@chu.ulg.ac.be.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial Sophie De Niet 1, * , Mickaël Trémège 1 , Monte Coffiner 1 , Anne-Francoise Rousseau 2 , Doriane Calmes 3 , Anne-Noelle Frix 3 , Fanny Gester 3 , Muriel Delvaux 3 , Anne-Francoise Dive 3 , Elora Guglielmi 3 , Monique Henket 3 , Alicia Staderoli 3 , Didier Maesen 4 , Renaud Louis 3 , Julien Guiot 3 and Etienne Cavalier 5 1 2 3 4 5 * Citation: De Niet, S.; Trémège, M.; Coffiner, M.; Rousseau, A.-F.; Calmes, D.; Frix, A.-N.; Gester, F.; Delvaux, M.; Dive, A.-F.; Guglielmi, E.; et al. Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2022, 14, 3048. https://doi.org/ 10.3390/nu14153048 Academic Editor: Connie Weaver Received: 8 June 2022 Accepted: 19 July 2022 Published: 26 July 2022 Clinical Department, Laboratoires SMB SA, 1080 Brussels, Belgium; mtrem@smb.be (M.T.); mcoff@smb.be (M.C.) Department of Intensive Care, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium; afrouseau@chuliege.be Department of Pneumology and Allergology, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium; d.calmes@chuliege.be (D.C.); affrix@chuliege.be (A.-N.F.); f.gester@chuliege.be (F.G.); muriel.delvaux@chuliege.be (M.D.); af.dive@chuliege.be (A.-F.D.); elora.guglielmi@chuliege.be (E.G.); monique.henket@chuliege.be (M.H.); alicia.staderoli@chuliege.be (A.S.); renaud.louis@chuliege.be (R.L.); j.guiot@chuliege.be (J.G.) Department of Hospital Pharmacy, CHU Sart-Tilman, 4000 Liège, Belgium; dmaesen@chuliege.be Department of Clinical Chemistry, University of Liège, CIRM, CHU Sart-Tilman, 4000 Liège, Belgium; etienne.cavalier@chu.ulg.ac.be Correspondence: sdeni@smb.be; Tel.: +32-2-411-4828 Abstract: Retrospective studies showed a relationship between vitamin D status and COVID-19 severity and mortality, with an inverse relation between SARS-CoV-2 positivity and circulating calcifediol levels. The objective of this pilot study was to investigate the effect of vitamin D supplementation on the length of hospital stay and clinical improvement in patients with vitamin D deficiency hospitalized with COVID-19. The study was randomized, double blind and placebo controlled. A total of 50 subjects were enrolled and received, in addition to the best available COVID therapy, either vitamin D (25,000 IU per day over 4 consecutive days, followed by 25,000 IU per week up to 6 weeks) or placebo. The length of hospital stay decreased significantly in the vitamin D group compared to the placebo group (4 days vs. 8 days; p = 0.003). At Day 7, a significantly lower percentage of patients were still hospitalized in the vitamin D group compared to the placebo group (19% vs. 54%; p = 0.0161), and none of the patients treated with vitamin D were hospitalized after 21 days compared to 14% of the patients treated with placebo. Vitamin D significantly reduced the duration of supplemental oxygen among the patients who needed it (4 days vs. 7 days in the placebo group; p = 0.012) and significantly improved the clinical recovery of the patients, as assessed by the WHO scale (p = 0.0048). In conclusion, this study demonstrated that the clinical outcome of COVID-19 patients requiring hospitalization was improved by administration of vitamin D. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit